Jeffrey A. LeerinkChairman and CEO

Jeffrey A. Leerink is the Chairman and CEO of Leerink Swann, a leading investment bank specializing in healthcare.  Leerink Swann provides merger and acquisition advisory services and access to equity capital markets for healthcare companies for which Leerink Swann has raised more than $15 billion of growth capital.

Mr. Leerink sits on the Board of Directors of Humedica, Inc., a next generation clinical informatics company, is a member of the Board of Fellows for Harvard Medical School and is a member of the Therapeutics Advisory Council at The Harvard Medical School Program in Translational Science and Therapeutics. He also actively supports a number of charitable organizations and sits on the board of Big Brothers Big Sisters of Massachusetts Bay. Mr. Leerink was born in Massachusetts, and received his B.A. in Economics from Union College.

Daniel B. Dubin, M.DVice Chairman, Chief Knowledge Officer and Founder of MEDACorp

Daniel B. Dubin has been an advisor to institutional investors and corporate life sciences clients since 1996. Dr. Dubin is also a member of the Management Committee and Chair of the Commitment Committee at Leerink Swann.

He was an instructor in Dermatology at Harvard Medical School and has held staff appointments at the Brigham and Women's Hospital and Dana Farber Cancer Institute. While at Brigham and Women's Hospital, he served as Ambulatory Medical Director of Clinical Dermatology and as a member of the Clinical Executive Committee.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in internal medicine and a residency in Dermatology at Massachusetts General Hospital. He has published over 30 manuscripts in medical journals and textbooks and performed a NIH training fellowship at the Harvard Skin Disease Research Center. He serves as a Director of Leerink Swann, Eleme Medical, and NanoBio Corporation. He is the former Chairman of MetaWorks, Inc.

Jeffrey S. AroySenior Managing Director, Head of Consulting

Jeffrey S. Aroy, Senior Managing Director, Head of Leerink Swann Consulting, has over 19 years of experience as a consultant and executive in life sciences.

In his five years with Leerink Swann, Mr. Aroy has helped life sciences companies develop and implement growth strategies in a variety of therapeutic areas. Prior to joining Leerink, with The Wilkerson Group/IBM Healthcare Consulting, Mr. Aroy was the Practice Leader for Medical Device and Diagnostic Consulting as well as the head of the West Coast Practice. Mr. Aroy also served as COO of Cholestech, an $85M diagnostics company sold to Inverness Medical for $326M and served as General Manager of Berkeley HeartLab, a $65MM advanced cardiovascular diagnostics company sold to Celera for $195M.

Prior to his executive roles, Mr. Aroy worked for four years in life sciences for Deloitte Consulting. Mr. Aroy received his BA in Economics from Harvard University and his MBA in Strategic Management from The Wharton School.

James BoylanSenior Managing Director, Head of Investment Banking

James (Jim) Boylan joined Leerink Swann in 2009 as Senior Managing Director, Head of Investment Banking. Mr. Boylan brings 20 years of experience to the Firm. He built his investment banking career at Merrill Lynch over the past 12 years both as an M&A specialist and a healthcare origination banker with a focus on life sciences, medical device and healthcare services companies. 

Mr. Boylan's deal resume includes more than 80 completed transactions where he helped clients complete the full spectrum of M&A and financing transactions.  Recent notable transactions include advising Celgene on its acquisition of Pharmion and advising Lifecell on its sale to Kinetic Concepts.
Mr. Boylan earned his M.B.A. from Columbia University and a B.S. from Lehigh University.

Joseph GentileChief Administrative Officer

Joseph Gentile joined the Firm in 2007 as Chief Administrative Officer. Mr. Gentile was formerly CFO, Global Investment Bank at Lehman Brothers, where he directed the accounting and financial needs within the Fixed Income division, the largest operating division of Lehman Brothers.

Prior to that, he served as CFO of the Global Corporate and Investment Bank at Bank of America, where he led the Capital Markets Division. Previously, Mr. Gentile spent more than 10 years with J.P. Morgan in various financial management positions, including Global Head of Financial Risk Management. He holds a B.S. in accounting and MBA in finance from St. John's University.

Timothy A.G. GerholdGeneral Counsel

Timothy Gerhold joined the Firm in 2006 as its General Counsel and Senior Managing Director of the Compliance and Legal Group.

Prior to joining the Firm, Mr. Gerhold was the General Counsel and Head of Compliance of BancBoston Capital, one of the largest bank-affiliated private equity groups in the United States. Before that, Mr. Gerhold held a number of positions in the Law Office of BankBoston Financial Corporation, including Group Head of the Capital Markets Group and Group Head of the Financial Services Group.

Previously, Mr. Gerhold practiced law at Goodwin Proctor LLP. Mr. Gerhold received his B.A. from Carleton College, and his J.D. from Yale Law School.

Robert LeerinkManaging Director, Head of Institutional Sales

Robert Leerink has been with Leerink Swann since its inception in 1995. He has been a Managing Director in Leerink Swann's Institutional Sales group since 2000.

Prior to joining Institutional Sales, Mr. Leerink led the Private Client Services group at Leerink Swann. He began his career in the private client services division of Fechtor Detwiler. Mr. Leerink holds a bachelor's degree from Babson College.

John S. McPheeSenior Managing Director, Wealth Management

John McPhee has been with Leerink Swann since its inception in 1995. From 1995 to 2004, John built a successful wealth management business focusing on the needs of healthcare and life science professionals. In 2004, Mr. McPhee was named the Head of Private Client Service and in 2006 launched the Middle Market institutional sales effort. In 2009 he started the Physician Network Services group, which was established to advise healthcare organizations and their employees on key issues such as physician recruitment, retention, and financial counseling.

Mr. McPhee is a Registered Securities Principal as well as a Registered Options Principal. Mr. McPhee is a graduate of Bentley College with a B.S. in Finance.

Mark RathjenManaging Director, Head of Institutional Trading

Mark Rathjen has been trading securities for over 15 years. Prior to joining Leerink Swann in 2005, Mr. Rathjen was VP Equities at Goldman Sachs. Previously, he served as Senior Vice President and Trading Desk Manager at Spear, Leeds & Kellogg Capital Markets. Mr. Rathjen began his career at NYSE specialist firm, Ernst Holmes. He holds a B.A. in Business from St. Bonaventure University.

John L. Sullivan, CFAManaging Director, Head of Equity Research

John L. Sullivan is Director of Research at Leerink Swann and its Healthcare Investment Strategist. As a sector analyst, Mr. Sullivan recently ranked #3 in The Wall Street Journal’s 2008 “Best on the Street” analysts’ survey. As a stock picker in 2007, he earned a #2 ranking among the life sciences tools and services analysts ranked by Starmine in Forbes.com and a #3 ranking among the same group for accuracy of his earnings estimates.

Previously, Mr. Sullivan was a Vice President, Senior Equity Research Analyst, Life Sciences, at Stephens Inc. where his primary focus was on companies possessing enabling technologies for health care-related products for research and drug discovery. Mr. Sullivan, a Chartered Financial Analyst, received his Bachelor of Science degree from Boston University and an MBA from J.L. Kellogg Graduate School of Management at Northwestern University.